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Abstract
Background: Data on determinants of long-term disease progression in HIV-infected patients on antiretroviral therapy (ART)
are limited in low and middle-income settings.
Methods: Effects of current CD4 count, viral load and haemoglobin and diagnosis of AIDS-defining events (ADEs) after start
of combination ART (cART) on death and new ADEs were assessed using Poisson regression, in patient aged $18 years
within a multi-centre cohort in Thailand.
Results: Among 1,572 patients, median follow-up from cART initiation was 4.4 (IQR 3.6–6.3) years. The analysis of death was
based on 60 events during 6,573 person-years; 30/50 (60%) deaths with underlying cause ascertained were attributable to
infections. Analysis of new ADE included 192 events during 5,865 person-years; TB and Pneumocystis jiroveci pneumonia
were the most commonly presented first new ADE (35% and 20% of cases, respectively). In multivariable analyses, low
current CD4 count after starting cART was the strongest predictor of death and of new ADE. Even at CD4 above 200 cells/
mm
3, survival improved steadily with CD4, with mortality rare at $500 cells/mm
3 (rate 1.1 per 1,000 person-years).
Haemoglobin had a strong independent effect, while viral load was weakly predictive with poorer prognosis only observed
at $100,000 copies/ml. Mortality risk increased following diagnosis of ADEs during cART. The decline in mortality rate with
duration on cART (from 21.3 per 1,000 person-years within first 6 months to 4.7 per 1,000 person-years at $36 months) was
accounted for by current CD4 count.
Conclusions: Patients with low CD4 count or haemoglobin require more intensive diagnostic and treatment of underlying
causes. Maintaining CD4$500 cells/mm
3 minimizes mortality. However, patient monitoring could potentially be relaxed at
high CD4 count if resources are limited. Optimal ART monitoring strategies in low-income settings remain a research
priority. Better understanding of the aetiology of anaemia in patients on ART could guide prevention and treatment.
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Introduction
By the end of 2009, 5 of the 33 million HIV-infected patients in
low- and middle-income countries were receiving antiretroviral
therapy (ART) [1]. Minimizing long-term morbidity and mortality
in patients on ART becomes increasingly important as treatment
programmes mature, standard of care improves and more effective
drug combinations are available. This has led to increased debate
on optimal approaches for monitoring antiretroviral treatment in
low-income settings [2]. Accurate data on determinants of long-
term disease progression in treated patients may therefore inform
patient management guidelines and research directions.
Differences between low and high-income settings such as
patients’ characteristics at presentation to HIV medical services,
PLOS ONE | www.plosone.org 1 August 2012 | Volume 7 | Issue 8 | e43375prevalence of co-morbidities, distribution of AIDS-defining
illnesses, spectrum of causes of death, and clinical management
have generally been observed [3]. It is therefore important to
assess not only key predictors of long-term outcomes in patients on
ART for different settings, but also the nature of these associations.
So far, analyses from low and middle-income settings on
prognostic factors in treated patients have mostly considered
baseline characteristics only and/or included relatively short-term
follow-up [3,4,5,6,7,8,9,10,11]. Only a few have assessed effects of
CD4 count and other laboratory markers while on ART on long-
term outcomes [12,13,14,15,16]. Consistent with data from
Europe and North America [17,18,19,20,21], these showed
current CD4 cell count was the strongest predictor of mortality
[13,14,16] and current haemoglobin independently predictive
[13,16]. The effect of current viral load was not consistently
observed across studies [13,14,16]. However, some of these studies
from low-income settings had certain limitations, including: the
effect of current CD4 count was estimated without adjusting for
current viral load and other markers [12,15]; CD4 count was
categorised in analysis with levels above 200 cells/mm
3 combined,
restricting scope to identify whether there is a target threshold
above which CD4 level should be maintained to minimise
mortality [12,16]; and information on cause of death was not
reported, limiting interpretation [13,14,15].
Using data from a multi-centre cohort in Thailand, a middle-
income country, we assessed the prognostic effects of CD4 count,
viral load and haemoglobin at start of combination antiretroviral
therapy (cART) and after treatment initiation on progression to
death and to first new ADE. The effect of new ADE on death was
also examined.
Methods
Ethics Statement
The Program for HIV Prevention and Treatment (PHPT)
cohort was approved by the Thai Ministry of Public Health and
local ethics committees. Participants provided written informed
consent at entry.
Study Background
The PHPT adult cohort prospectively followed HIV-infected
patients receiving ART in 40 public hospitals across Thailand
(NCT00433030 www.clinicaltrials.gov). The study has been
previously described [22]. Briefly, the cohort began in 1999,
recruiting women from trials on prevention of mother-to-child
transmission of HIV (PMTCT) [23,24], and later extended to
partners of these women and any HIV-infected adults presenting
at participating sites. The criteria for initiation of therapy was
CDC clinical stage B/C or CD4,250 cells/mm
3 [25]. Initial
HAART regimens changed over time with increased availability of
drugs. Alternative drugs were available in case of intolerance or
confirmed virologic failure. Cotrimoxazole and fluconazole
prophylaxis were prescribed as needed. Patients attended the
clinic monthly for physical examination, drug refills and adherence
counselling conducted by a nurse. They were also reviewed by a
physician every month during the first 3 months of treatment and
at 3-monthly intervals thereafter, with additional referrals as
required. CD4 and virology testing and a complete blood cell
count were done at start of treatment, at 3 months and every
6 months thereafter. Cause of death was reported by site
physicians, and further reviewed and classified by two independent
physicians based on ICD-10 classification (http://www.who.int/
classifications/icd/en/index.html).
Statistical Analyses
Patients were included in these analyses if they were ART naı ¨ve
at PHPT cohort enrolment (apart from treatment received for
PMTCT), subsequently started cART with at least 3 antiretroviral
drugs at age 18 years or older, and had at least one CD4 and one
viral load evaluation after cART initiation.
Outcomes evaluated were progression from cART initiation to
(i) all-cause mortality and (ii) first new ADE (which included death
in the absence of a new AIDS diagnosis after starting cART). In
the analysis of new ADE, patients with AIDS diagnosis before
starting cART were included and progression to the first clinically
new ADE was considered, ignoring recurrence of ADE’s occurring
before cART initiation. Follow-up was considered from date
starting cART up to the date of the outcome of interest or date of
last clinic visit for patients censored.
At a given time point, we defined current CD4 count, viral load
or haemoglobin as the most recent measurement taken after
cART initiation which was within the last 9 months of that time
point. The value at cART initiation was defined as the most recent
measurement within 6 months prior to date of initiation. We
classified ADEs as either mild or moderate/severe, based on
prognostic categories proposed in a Antiretroviral Therapy Cohort
Collaboration (ART-CC) study which showed different types of
ADE diagnosed after cART initiation had varying impact on
mortality [26].
First, we examined the predictive value of the following time-
varying factors: current CD4 count; current viral load; current
haemoglobin; time since cART initiation; and for progression to
death only, diagnosis of new mild ADEs and of new moderate/
severe ADEs after cART initiation. The effect of type of new
ADEs on mortality was assessed based on patients without prior
AIDS diagnosis at cART initiation, consistent with the ART-CC
study [26]. Time-dependent indicator variables corresponding to
before and after diagnosis of the first event (s) within each ADE
prognostic category were fitted.
We then assessed whether after accounting for current CD4
count, viral load and haemoglobin, there were any additional
prognostic value in CD4 count, viral load, haemoglobin and AIDS
diagnosis status at cART initiation.
Effects of covariates were estimated using Poisson regression
models, based on follow-up periods with both current CD4
count and viral load available. Clustering within hospitals was
included as a random effect. Multivariable analyses were
adjusted for time since cART initiation (split according to
,6 months, 6–11.99, 12–23.99, 24–35.99 and $36 months),
current CD4 count, viral load and haemoglobin and, in
addition, the following a priori confounders at initiation which
were selected on the basis of findings from previous studies
[7,22,27,28]: sex, HBV and HCV status, CD4 count, viral load,
haemoglobin, age, calendar period (before 2005, 2005 onwards),
AIDS diagnosis status, and whether ART-naı ¨ve when starting
cART.
CD4 count was square root transformed to improve model
fit. Current viral load was categorized as ,400, 400 to 99,999
and $100,000 copies/ml; these categories were chosen since the
detection limit of assays used had varied over time and a
previous study showed high viral load at 6 months from starting
treatment was associated with poorer survival but only at levels
above 100,000 copies/ml [29]. Viral load and age at cART
initiation were log transformed. Non-linear effects were assessed
for using cubic spline terms with knots at the 10
th,5 0
th and 90
th
centiles [30]. Non-proportional hazards were assessed by testing
for interaction between covariates and follow-up time (catego-
rised as less or greater than 2 years from cART initiation).
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using Multivariate Imputation by Chained Equations based on
20 cycles [31].
Finally, we carried out sensitivity analyses with: (i) current CD4
count, viral load and haemoglobin defined assuming a given
measurement was valid for a maximum of 6 and 12 months,
Table 1. Patients’ characteristics at cART initiation (N=1572).
Number of patients (%)
a
Female sex 1192 (76%)
HBV antigen positive 93 (6%)
Anti-HCV seropositive 49 (4%)
Previous ART treatment
None (except for PMTCT ART use) 1462 (93%)
Dual therapy 110 (7%)
Age (years)
median (IQR) 32.7 (28.5–38.1)
,30 541 (34%)
30–39 736 (47%)
40–49 243 (15%)
$50 52 (3%)
Year started cART
2001–2002 270 (17%)
2003–2004 406 (26%)
2005–2006 766 (49%)
2007–2010 130 (8%)
CD4 cell count (cells/mm
3)
median (IQR) 129 (59–198)
,50 324 (21%)
50–99 299 (17%)
100–149 258 (17%)
150–199 282 (18%)
200–349 342 (22%)
$350 35 (2%)
Viral load (log copies/ml), median (IQR) 4.8 (4.3–5.2)
Haemoglobin (g/dl)
median (IQR) 11.7 (10.6–2.8)
,8 18 (1%)
8–9.99 199 (13%)
10–11.99 627 (41%)
$12 669 (44%)
AIDS diagnosis before cART initiation 344 (22%)
No 1224 (78%)
Previously diagnosed with mild ADE (s) only
b 247 (16%)
Previously diagnosed with moderate/severe ADE (s)
b 101 (6%)
Initial cART regimen
Efavirenz+ NRTI’s 584 (37%)
Nevirapine + NRTI’s 199 (13%)
PI + NRTI’s 743 (47%)
NNRTI + PI + NRTI’s 46
c (3%)
cART, combination antiretroviral therapy; HBV, hepatitis B virus; HCV, hepatitis C virus; PMTCT, prevent of mother-to-child transmission; ADE, AIDS-defining event;
NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; IQR, inter-quartile range.
aPercentage based on total with data available. Number with missing data: sex (1), HCV status (269), CD4 count (32), HIV-1 RNA (137), haemoglobin (59).
bADEs were defined as either mild or moderate/severe based on prognostic categories proposed by Mocroft et al [26]. Note only 2 patients were previously diagnosed
with a severe ADE.
cThe 46 patients starting with regimens containing NNRTI+PI were all previously on dual therapy.
doi:10.1371/journal.pone.0043375.t001
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to each nominal time points within a63 months window was selected for each patient.
doi:10.1371/journal.pone.0043375.g001
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ART-naı ¨ve at cART initiation (apart from ART use for PMTCT).
All statistical analyses were undertaken in STATA, version 11.
Results
1740 patients were ART-naı ¨ve at PHPT cohort enrolment and
subsequently started cART aged $18 years between 2001 and
2010. Of these, 1572 (90%) had follow-up period (s) after initiation
with both current CD4 count and viral load measures and were
included in analyses.
Characteristics at cART Initiation
Three-quarters (76%) of patients were female; Table 1. At
cART initiation, median age was 32.7 (IQR 28.5–38.1) years and
CD4 count 129 (59–198) cells/mm
3. Women had lower haemo-
globin than men, with median 11.5 (IQR 10.5–12.4) versus 12.8
(11.4–14.2), respectively. A small proportion of patients (7%,
n=110) previously received ART for their HIV, all initially
prescribed didanosine plus stavudine dual therapy at median 2.9
(IQR 2.2–3.3) years before switching to cART. Around a fifth of
patients (22%, n=344) were diagnosed with AIDS before cART
initiation.
Follow-up after cART Initiation
Patients were followed up for a median 4.4 (IQR 3.6–6.3) years
after starting cART. 145/1572 (9%) patients were lost to follow-up
after cART initiation and 149 (9%) voluntarily withdrew. Median
number of measurements per patient after initiation was 14 (IQR
11–17) for CD4 count, 14 (10–16) for viral load and 20 (16–27) for
haemoglobin.
Trends in CD4 Cell Count, Viral Load and Haemoglobin
after cART Initiation
The proportion of patients with HIV-1 RNA ,400 copies/ml
was 91.3% at 6 months from cART initiation, and around 95%
from 3 years onwards (Figure 1). At 12 months, 11% of patients
with viral load suppression ,400 copies/ml attained CD4 level
$500 cells/mm
3, increasing to 35% and 52% at 3 and 5 years,
respectively. High CD4 count at cART initiation was associated
with high absolute level at all subsequent times (data not shown).
Haemoglobin increased following cART though mainly within the
first year, with lower levels observed in women throughout follow-
up (data not shown).
Follow-up and Events Contributing to Analyses of
Disease Progression
The analysis of progression to death was based on 60 deaths
during 6573 person-years (90% of total follow-up from cART
initiation) when both current CD4 count and viral load were
available; Table 2. Cause of death was ascertained in 50/60 (83%)
of cases. Of these, 30 (60%) died of infection-related causes
(10 tuberculosis, 7 cryptomeningitis, 4 pneumonia, 1 toxoplasmo-
sis, 1 meningitis, 2 septicaemia, 1 cellulitis, 1 disseminated/gen-
eralized fungal infection, 1 complication related to hepatitis C co-
infection, 1 human papillomavirus infection and 1 cholecystitis)
and 20 (40%) of other causes (9 cardiovascular disease, 3 cancer,
1 liver failure, 1 asthma, 4 suicide, 1 alcohol abuse and 1
accident). Among deaths with underlying cause ascertained, those
occurring within the first 2 years of cART were more likely to be
due to infection-related causes (24/34, 71%) compared with after
(6/16, 38%) (p=0.03). Patients with infection-related causes of
death had substantially lower CD4 count and haemoglobin and
were less likely to be suppressed ,400 copies/ml at the time of
death compared with those dying of other known causes; Figure 2.
In the analysis of progression to first new ADE, 69 of the 1572
patients developed a new ADE after cART initiation but prior to
any CD4 and viral load evaluation while on treatment, so were
excluded; of these, 80% (n=55) developed a new ADE within
6 months, 46% (n=32) within 3 months. Among the remaining
1503 patients included, there were 192 events during 5865 person-
years (Table 2); 153 patients developed $1 new ADE (s) and 39
died without developing a new ADE. Eleven (7%) of the 153
patients developing new ADE (s) presented simultaneously with
two or more ADEs at initial diagnosis. The most common first new
ADE were: TB (diagnosed in 35% of the 153 patients), Pneumocystis
jiroveci pneumonia (20%), generalized herpes simplex infection
(10%) and recurrent pneumonia (5%).
Associations with Progression to Death
The associations with mortality for factors after cART initiation
are shown in Table 3. Mortality rate was 124.8 per 1000 person-
years at CD4 count ,100 cells/mm
3, decreasing substantially to
Table 2. Number of patients, events and years of follow-up contributing to analyses.
Analysis of progression to death
Analysis of progression to first new
ADE
Number of patients 1572 1503
a
Total follow-up (years) 6573 5865
Total number of events 60 192
b
Time from cART initiation to event (months)
,6 5 (8%) 27 (14%)
6–11.99 12 (20%) 29 (15%)
12–23.99 21 (35%) 65 (34%)
24–35.99 9 (15%) 32 (17%)
$36 13 (22%) 39 (20%)
ADE, AIDS-defining event; cART, combination antiretroviral therapy.
a69 of the 1572 patients included in analyses of progression to death developed a new ADE after cART initiation but before having at least 1 CD4 count and viral load
evaluation while on treatment, and therefore were excluded in the analyses of progression to first new ADE.
b153 patients progressed to $1 new ADE (s), while 39 patients died without having a new ADE after starting cART.
doi:10.1371/journal.pone.0043375.t002
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3. In multivariable
analyses, low level of current CD4 count (p,0.001) and
haemoglobin (p,0.001) were the strongest predictors of mortality.
Current viral load had a weak independent effect (p=0.05), with
poorer survival associated with levels $100,000 copies/ml. As
expected, mortality rate declined steadily with time from cART
initiation, from 21.3 per 1000 person-years during the first
6 months to 4.7 per 1000 person-years at $36 months; however,
this trend disappeared after adjusting for current CD4 count
(p=0.82), but not when only either current viral load (p=0.01) or
haemoglobin (p=0.006) were accounted for.
Table 4 shows the predictive effects of factors at cART initiation
after adjusting for current CD4 count, haemoglobin and viral
load. At a given current CD4 count value, lower CD4 count at
cART initiation was weakly associated with decreased mortality,
indicating better prognosis with greater increase in CD4 count
from baseline. Viral load and haemoglobin at cART initiation had
no effect.
Prior AIDS diagnosis before cART initiation was not predictive
of mortality (Table 4). However, among patients not diagnosed
with AIDS before starting cART, subsequent diagnosis of mild
ADEs and of moderate/severe ADEs after initiation were both
associated with mortality, with their impact being similar (rate
ratio 4.2 [95% CI 1.9–9.7] and 5.3 [1.8–15.8], respectively;
Table 3).
Associations with Progression to New ADE
Current CD4 count (p,0.001) and haemoglobin (p,0.001)
were both strongly prognostic of new ADE, though the magnitude
of these associations was weaker compared with that for death
(Table 3). Viral load was weakly predictive with increased risk only
at levels $100,000 copies/ml (p=0.03), as observed for mortality.
Risk of new ADE remained higher during the first 6 months of
cART initiation after accounting for current CD4 count, viral load
and haemoglobin (p,0.001), but was constant thereafter
(p=0.73).
After adjusting for current CD4 count, viral load and
haemoglobin, higher viral load at cART initiation remained
strongly associated with new ADE (p,0.001, Table 4), with its
effect similar within the first 2 years of initiation compared to after
(non-proportional hazards p-value 0.50). CD4 count and haemo-
golobin at cART initiation had no effect. Patients with moderate/
severe ADE (s) before cART initiation had increased risk of new
ADE, but not those with mild ADE (s) only (p,0.001).
Sensitivity Analyses
Results remained the same when either (i) current CD4 count
and viral load were defined by assuming a given measurement was
valid for a maximum of 6 or 12 months or (ii) patients who
initiated on dual therapy before switching to cART were excluded.
Discussion
This study was based on a well-run, long-term ART programme
involving a wide range of public hospitals throughout Thailand,
with good quality data collection including accurate ascertainment
of AIDS diagnoses and cause of death for most patients. Consistent
with other studies from low and high-income settings, CD4 count
was found to be the strongest predictor of death and of new ADE
[13,14,18,19,21]. In our cohort, the decline in mortality rate over
time from cART initiation (well-documented particularly in low-
income settings [6,13]) was accounted for by current CD4 count,
further underlining its key role as an immediate prognostic
indicator. As expected, mortality rate at CD4 count ,100 cells/
mm
3 was substantially high (124.8 per 100 person-years).
Therefore, patients with low CD4 count, even if virologically
suppressed, should be closely monitored, with underlying causes of
Figure 2. Distribution of most recent CD4 count (A), viral load
(B) and haemoglobin (C) measurement at time of death, by
cause of death. Based measurements within the last 9 months before
date of death. Number of cases by cause of death: 10 TB, 20 other
infections, 20 not related to infection and 10 not known.
doi:10.1371/journal.pone.0043375.g002
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ditions) promptly investigated and addressed.
We observed improved survival with increasing CD4 count
even at levels above 200 cells/mm
3, with mortality being rare at
$500 cells/mm
3 (rate 1.1 per 1000 person-years). A recent
analysis of four large treatment cohorts from Sub-Saharan Africa
reported a 1.7 fold increase in mortality risk at CD4 levels 350–
499 cells/mm
3 compared to $500 cells/mm
3 (adjusted for only
baseline characteristics and calendar period), comparable to our
estimate of 2.5 (95% CI 1.9–3.4) [15]. Furthermore, a French
study showed patients on long-term cART with CD4 count
.500 cells/mm
3 had similar mortality rates as the general
population [32]. These findings provide growing evidence of the
benefit of maintaining CD4 count above 500 cells/mm
3 while on
treatment. They also suggest that relaxing monitoring for patients
on treatment with high stable CD4 count should be evaluated for
settings with limited capacity for CD4 monitoring. In addition,
early HIV diagnosis and early treatment initiation before onset of
severe immunosuppression are indicated, given that high CD4
count at ART initiation is associated with improved long-term
CD4 cell count recovery [3,21,33]; the effect on long-term
outcomes of starting ART at CD4 count .500 cells/mm
3
compared to deferring until CD4 falls below 350 cells/mm
3 is
being investigated in the ongoing randomized START trial [34].
Previous studies across different settings already showed the
independent association between low haemoglobin on cART and
disease progression [13,16,18,19,20,35], as also observed in our
study. The link between low haemoglobin and mortality is not
well-understood and appears multifactorial, but is likely to be
partly due to anaemia being an indicator of other co-morbidities,
particularly tuberculosis [35,36,37]. Consistent with this, we found
80% of patients dying of tuberculosis had haemoglobin level
Table 3. Predictive effects of factors after cART initiation on progression to death and to new ADE.
Factors Progression to death Progression to first new ADE
Rate per 1000 py
(events/py)
Adjusted rate ratio
a
(95% CI) p-value
Rate per 1000 py
(events/py)
Adjusted rate ratio
a
(95% CI) p-value
Current CD4 count (cells/mm
3)
,100 124.8 (24/192) 33.6 (10.6–106.5)
b ,0.001 290.7 (44/151) 4.6 (2.5–8.4)
b ,0.001
100–199 16.0 (11/686) 12.8 (5.6–29.7) 59.9 (36/601) 2.6 (1.6–4.1)
200–349 7.7 (15/1951) 5.4 (3.1–9.3) 34.5 (61/1769) 1.7 (1.1–2.6)
350–499 4.2 (8/1917) 2.5 (1.9–3.4) 18.3 (32/1753) 1.1 (0.8–1.6)
$500 1.1 (2/1826) 1 11.8 (19/1613) 1
Current viral load (copies/ml)
,400 7.1 (44/6180) 1 0.05 27.4 (152/5546) 1 0.03
400–99,999 14.6 (5/343) 0.5 (0.2–1.5) 73.5 (22/299) 1.3 (0.8–2.2)
$100,000 218.9 (11/50) 2.1 (0.8–5.6) 429.8 (18/42) 2.4 (1.2–4.8)
Current haemoglobin (g/dl)
,8 419.4 (8/19) 12.0 (5.7–25.1)
b ,0.001 530.8 (9/17) 4.1 (2.3–7.1)
b ,0.001
8–9.99 43.0 (10/233) 4.4 (2.8–6.8) 122.2 (24/196) 2.3 (1.7–3.2)
10–11.99 10.7 (20/1877) 1.8 (1.4–2.2) 34.1 (58/1701) 1.4 (1.2–1.6)
$12 4.8 (21/4417) 1 23.8 (94/3955) 1
Diagnosis of new mild ADEs after cART initiation
c
Before diagnosis 5.9 (29/4900) 1 –
After initial diagnosis 36.2 (10/276) 4.2 (1.9–9.7) 0.001
Diagnosis of new moderate/severe ADEs after cART initiation
c
Before diagnosis 6.7 (34/5038) 1 –
After initial diagnosis 36.2 (5/138) 5.3 (1.8–15.8) 0.003
Time since cART initiation (months)
,6 21.3 (5/235) 1 0.86 118.4 (27/228) 1 ,0.001
6–11.99 16.5 (12/726) 1.0 (0.3–2.9) 42.4 (29/683) 0.3 (0.2–0.6)
12–23.99 14.5 (21/1445) 1.4 (0.5–3.8) 49.1 (65/1324) 0.5 (0.3–0.9)
24–35.99 6.5 (9/1376) 1.0 (0.3–3.1) 26.1 (32/1224) 0.4 (0.2–0.7)
$36 4.7 (13/2790) 1.0 (0.3–3.1) 16.1 (39/2427) 0.3 (0.2–0.5)
cART, combination antiretroviral therapy; ADE, AIDS-defining event; py, person-years; CI, confidence interval.
aEffects were estimated adjusted for a priori confounders, time since cART initiation, and current CD4 count, viral load and haemoglobin. Current CD4 count and
haemoglobin, and CD4 count, viral load and haemoglobin at cART initiation were analysed as continuous variables.
bTo present the estimated effect of CD4 count (fitted square root transformed) and current haemoglobin (fitted with additional cubic spline term), we derived from the
fitted model the rate at the marker value at which 50% of person-years of follow-up falls above and below within each strata, and then calculated the corresponding
rate ratios.
cBased on patients without prior AIDS diagnosis before cART initiation. Only 1 patient was diagnosed with a severe ADE after starting cART, who had progressive
multifocal leukoencephalopathy.
doi:10.1371/journal.pone.0043375.t003
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to other infections and none of those due to non-infection related
causes. Although haemoglobin level was lower in women
throughout follow-up in our cohort, its prognostic value did not
vary by gender (data not shown), consistent with results from a
previous UK study [20].
In our cohort, high current viral load was weakly associated
with both mortality and new ADE but only at $100,000 copies/
ml, consistent with a previous ART-CC study [29]. Other studies
from low- and high-income settings generally reported a modest
association between lack of viral load suppression and poor
prognosis [14,18,19]. In a large cohort from South Africa, viral
load was more strongly prognostic after 12 months, suggesting that
viral load monitoring may be more informative after 1 to 2 years
of cART [13]. Given the need to prevent accumulation of
resistance on a virologically failing regimen, development of viral
assays which are cheap, practical and reliable for use in low-
income settings remains important for improving patient moni-
toring [38]. Of interest, high viral load at cART initiation
remained predictive of new ADE/death (but not of death) after
adjusting for subsequent viral load and CD4 measurements. The
explanation for this association, which has not been previously
reported, is unclear but could partly be due to delay in diagnosis of
certain pre-existing conditions at the time of cART initiation.
Substantial variation in the impact of different ADEs on
mortality was previously observed in an ART-CC analysis
including treated patients in Europe and US [26]. When applying
the prognostic categories of ADEs proposed from this study to our
cohort, there was in fact little difference in the effect of mild
compared with moderate/severe ADEs on mortality. Our analysis
however only included one patient with a severe ADE (progressive
multifocal leukoencephalopathy) after starting cART. Further-
more, due to sparse data, we did not evaluate effects of individual
ADEs (as was done in the ART-CC analysis), but considered the
first event occurring within each ADE prognostic category.
In our study, rate of loss-to follow-up was relatively low, with
efforts made to trace patients missing clinic visits using telephone
calls and home visits. Although voluntary patient withdrawal from
the study was usually due to relocation or ART being accessed
elsewhere through the national treatment programs, it is important
to note that patients who were either lost to follow-up or
voluntarily withdrew were less likely to be virologically suppressed
after cART initiation compared to those still in follow-up, with loss
to follow-up also associated with lower CD4 attained (data not
shown). This could lead to under-estimation of the effects of CD4
count and viral load if patient drop-out was associated with
mortality or progression to new ADE’s, conditional on the
covariates in the models (including current CD4 count and viral
load).
A limitation to our analysis was that effects of covariates were
not assessed separately for AIDS-related and non AIDS-related
mortality due to limited number of deaths. An association between
CD4 count and non-AIDS related mortality has been reported,
albeit of weaker magnitude compared with that for AIDS-related
mortality [12]. This is consistent with our observation that patients
dying of causes not related to infection had higher CD4 count and
haemoglobin at the time of death compared to those dying of
infection(s), and were also more likely to be virologically
suppressed. Of note, we found patients were more likely to die
of non-infection related than infection-related causes after 2 years
of cART, indicating that ART monitoring potentially needs to
account for the changing patterns of mortality over time. Another
Table 4. Predictive effects of factors at cART initiation on progression to death and to new ADE, adjusted for current CD4 count,
haemoglobin and viral load.
Factors Progression to death Progression to first new ADE
Rate per 1000 py
(events/py)
Adjusted rate ratio
a
(95% CI) p-value
Rate per 1000 py
(events/py)
Adjusted rate ratio
a
(95% CI) p-value
CD4 count at initiation (cells/mm
3)
,100 12.0 (32/2657) 0.5 (0.3–1.0) 0.07 53.0 (115/2168) 1.4 (0.9–2.1) 0.11
100–199 8.2 (18/2206) 0.8 (0.6–1.0) 26.7 (55/2061) 1.1 (1.0–1.3)
$200 5.8 (9/1552) 1 12.5 (19/1515) 1
Viral load at initiation (copies/ml) 1.3 (0.9–1.9) per
log10(copies/ml)
0.23 1.6 (1.2–2.0) per
log10(copies/ml)
,0.001
,10,000 5.9 (6/1011) 12.2 (12/986)
10,000–99,999 5.5 (14/2561) 25.0 (58/2323)
$100,000 13.4 (31/2306) 53.3 (104/1950)
Haemoglobin at initiation (g/dl) 1.0 (0.9–1.1) per unit 0.93 1.0 (0.9–1.0) per unit 0.41
,8 12.9 (1/78) 110.7 (6/54.2)
8–9.99 21.1 (17/806) 59.0 (39/662)
10–11.99 7.4 (19/2561) 29.8 (69/2312)
$12 7.0 (20/2871) 20.7 (56/2710)
AIDS diagnosis before initiation
No 7.5 (39/5176) 1 0.20 24.7 (119/4816) 1 ,0.001
Mild ADE (s) only 10.1 (10/993) 0.9 (0.4–1.9) 44.8 (37/826) 1.2 (0.8–1.8)
Moderate/severe ADE (s) 27.2 (11/404) 1.9 (0.9–4.3) 147.1 (36/245) 3.0 (1.9–4.8)
cART, combination antiretroviral therapy; ADE, AIDS-defining event; py, person-years; CI, confidence interval.
aEffects were estimated adjusted for a priori confounders, time since cART initiation, and current CD4 count, viral load and haemoglobin.
doi:10.1371/journal.pone.0043375.t004
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new ADE were excluded from analyses owing to lack of laboratory
measurements after starting cART; risk factors of early mortality
in our cohort have been previously described [22]. Consequently,
only 14% of new ADEs and 8% of deaths occurred within
6 months of cART initiation, and while immune reconstitution
syndrome (IRIS) may account for some of these early events, it is
unlikely to play a significant role in our overall findings.
In conclusion, immunosuppression and anaemia may reflect the
presence or development of conditions that lead to mortality. Half
of the deaths in this Thai cohort were attributable to infections
which were chronic and generally considered treatable, while the
cause of death remained unknown in nearly a fifth despite regular
follow-up. This suggests a significant proportion of patients died of
conditions which were not diagnosed in time or appropriately
treated, possibly due to constraints in this resource-limited setting
and lack of experience in handling such complications at the
beginning of the program when the priority was given to starting
antiretroviral treatment for all those who urgently needed it.
Patients with low CD4 count or haemoglobin should therefore
receive more intensive case-management, while monitoring could
potentially be relaxed for those with high CD4 if resources are
limited. ART monitoring in low-income settings remains a
research priority, and in particular, better understanding of
predictors of morbidity and mortality due to non-AIDS disease
is needed given patients are surviving longer on treatment.
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